Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Analyst sentiment is positive: Ten analysts give Inventiva an average “Buy” rating, including six buys and three strong buys, versus one sell. The average 12-month price target is $15.375, well above the reported share price of $4.78.
• Institutional interest is growing: Several hedge funds recently initiated positions in Inventiva, while institutional investors collectively own 19.06% of the company.
• Shares remain volatile: Inventiva stock was down 1.2%, with a 52-week range of $3.35 to $7.98 and a 200-day moving average of $5.03. The clinical-stage biopharmaceutical company’s lead drug candidate, lanifibranor, is in Phase III development for NASH.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) have been assigned an average rating of "Buy" from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and three have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $15.3750.

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research report on Friday, July 17th. Cantor Fitzgerald started coverage on Inventiva in a report on Friday, July 17th. They issued an "overweight" rating on the stock.

Hedge Funds Weigh In On Inventiva

A number of hedge funds have recently bought and sold shares of the company. Creative Planning bought a new stake in Inventiva during the 2nd quarter valued at about $32,000. Virtu Financial LLC bought a new position in shares of Inventiva in the fourth quarter worth approximately $60,000. XTX Topco Ltd purchased a new stake in shares of Inventiva during the fourth quarter valued at approximately $84,000. NewEdge Advisors LLC purchased a new stake in shares of Inventiva during the third quarter valued at approximately $116,000. Finally, Cerity Partners LLC bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $93,000. Institutional investors own 19.06% of the company's stock.

Inventiva Trading Down 1.2%

IVA stock opened at $4.78 on Friday. The firm has a 50 day moving average price of $4.51 and a 200-day moving average price of $5.03. Inventiva has a 52-week low of $3.35 and a 52-week high of $7.98.

Inventiva Company Profile

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source